Edwards Lifesciences: Q2 2026 Earnings on Deck

Edwards Lifesciences Corporation (EW), a prominent global leader in structural heart innovation valued at $52.1 billion, is preparing to release its fiscal Q2 2026 financial results. As of July 3, 2026, analysts are forecasting an adjusted Earnings Per Share (EPS) of $0.73 for the quarter, marking a significant nearly 9% increase compared to $0.67 in the same period last year. This projection follows a trend where EW has exceeded Wall Street's earnings expectations in three of the last four quarters.

For the full fiscal year 2026, projections suggest an adjusted EPS of $3, an anticipated 17.2% rise from fiscal 2025's $2.56. While EW's stock has climbed 18.8% over the past 52 weeks, it has slightly trailed the S&P 500's 21.3% gain but outperformed the Health Care Select Sector SPDR ETF's 16.5% return. Following its Q1 2026 report on April 23, 2026, the stock saw a 5.6% increase due to strong sales growth and raised 2026 guidance across key areas, including TAVR and adjusted EPS.

The company's ongoing success is buoyed by the robust adoption of its SAPIEN TAVR platform and increasing demand for its EVOQUE, PASCAL, and SAPIEN M3 products. The analyst consensus for EW stock remains "Moderate Buy," with 19 out of 29 analysts recommending "Strong Buy." The average price target of $97.48 suggests a potential upside of 6.9% from current trading levels.